Daraxonrasib Toxicity Prevention and Management

Authored by Open Medicine, published on 2026-08-25 21:34:34.0

The algorithm follows broadly standard oncology supportive-care principles (baseline assessment, early monitoring, CTCAE grading, hold/reduce/rechallenge, and urgent escalation for suspected SCAR or severe toxicity). However, daraxonrasib and the referenced “RASolute 302” protocol appear investigational/brand- or trial-specific, so key operational details (dose modifications, interaction list, and SCAR-specific discontinuation rules) should be anchored to the actual study protocol and/or product label if available. The rash and mucositis management branches are generally consistent with established guidance for targeted-therapy dermatologic AEs and cancer therapy–associated oral mucositis.

  1. Confirmed Daraxonrasib Candidate On Therapy
    • Pre-Treatment Risk Review And Medication Reconciliation
      • Baseline Skin And Oral Exam With Photos
        • Baseline Labs And Monitoring Plan Before First Dose
          • Start Daraxonrasib With Rash And Oral Prophylaxis
            • Early Follow-Up And Scheduled Toxicity Monitoring
              • Any New Or Worsening Toxicity Reported
                • No Toxicity Continue Routine Monitoring Schedule
                • Grade Toxicity And Identify Likely Etiology
                  • Suspected Emergency Or Life-Threatening Presentation
                    • Hold Drug And Urgent Evaluation In ED
                      • Stabilize And Treat Per Organ-Specific Protocols
                        • Determine Rechallenge Eligibility And Risk Mitigation
                          • Permanently Discontinue And Transition To Next Therapy
                          • Resume At Reduced Dose With Close Monitoring
                  • Primary Toxicity Is Rash Or Pruritus
                    • Rash Grade 1 Continue And Intensify Prophylaxis
                      • Emollients And Sun Protection Standard Instructions
                        • Rash Improved To Grade 1 Or Better
                          • Restart Per RASolute 302 Hold-Reduce Rules
                          • Permanently Discontinue And Transition To Next Therapy
                    • Rash Grade 2 Start Rx Topicals And Reassess
                      • Add Topical Steroid And Oral Antihistamine
                        • Rash Improved To Grade 1 Or Better
                          • Restart Per RASolute 302 Hold-Reduce Rules
                          • Permanently Discontinue And Transition To Next Therapy
                    • Rash Grade 3 Hold Drug And Urgent Derm Consult
                      • Consider Systemic Steroid Per Protocol
                        • Rash Improved To Grade 1 Or Better
                          • Restart Per RASolute 302 Hold-Reduce Rules
                          • Permanently Discontinue And Transition To Next Therapy
                    • Rash Grade 4 Or SCAR Suspected
                  • Primary Toxicity Is Oral Pain Or Mucositis
                    • Start Salt-Soda Rinse And Alcohol-Free Mouthwash
                    • If Moderate Pain Add Doxepin Or Lidocaine Rinse
                    • If Severe Or Unable To Eat Hold Drug
                      • Restart Per Protocol After Mucositis Recovery
      • Screen For High Rash Risk And Alternatives
        • Check Baseline Dermatologic Conditions And Sun Exposure
          • Perform Drug Interaction Screen Before First Dose
            • Avoid Or Substitute High-Risk Interacting Drugs
              • Start Daraxonrasib With Rash And Oral Prophylaxis
                • Early Follow-Up And Scheduled Toxicity Monitoring
                  • Any New Or Worsening Toxicity Reported
                    • No Toxicity Continue Routine Monitoring Schedule
                    • Grade Toxicity And Identify Likely Etiology
                      • Suspected Emergency Or Life-Threatening Presentation
                        • Hold Drug And Urgent Evaluation In ED
                          • Stabilize And Treat Per Organ-Specific Protocols
                            • Determine Rechallenge Eligibility And Risk Mitigation
                              • Permanently Discontinue And Transition To Next Therapy
                              • Resume At Reduced Dose With Close Monitoring
                      • Primary Toxicity Is Rash Or Pruritus
                        • Rash Grade 1 Continue And Intensify Prophylaxis
                          • Emollients And Sun Protection Standard Instructions
                            • Rash Improved To Grade 1 Or Better
                              • Restart Per RASolute 302 Hold-Reduce Rules
                              • Permanently Discontinue And Transition To Next Therapy
                        • Rash Grade 2 Start Rx Topicals And Reassess
                          • Add Topical Steroid And Oral Antihistamine
                            • Rash Improved To Grade 1 Or Better
                              • Restart Per RASolute 302 Hold-Reduce Rules
                              • Permanently Discontinue And Transition To Next Therapy
                        • Rash Grade 3 Hold Drug And Urgent Derm Consult
                          • Consider Systemic Steroid Per Protocol
                            • Rash Improved To Grade 1 Or Better
                              • Restart Per RASolute 302 Hold-Reduce Rules
                              • Permanently Discontinue And Transition To Next Therapy
                        • Rash Grade 4 Or SCAR Suspected
                      • Primary Toxicity Is Oral Pain Or Mucositis
                        • Start Salt-Soda Rinse And Alcohol-Free Mouthwash
                        • If Moderate Pain Add Doxepin Or Lidocaine Rinse
                        • If Severe Or Unable To Eat Hold Drug
                          • Restart Per Protocol After Mucositis Recovery
  2. Insert RASolute 302 Dose Modification Table
    Populate exact daraxonrasib dose levels, first/second/third reduction steps, and permanent discontinuation rules from the RASolute 302 protocol (rash-specific and non-rash AEs). Include time-to-recovery thresholds and maximum interruption duration if specified.
  3. Define SCAR Red Flags And ED Triggers
    Specify protocol- or label-defined warning signs for SJS/TEN, DRESS, extensive blistering, mucosal involvement, facial edema, fever, hypotension, or rapid progression that mandate permanent discontinuation and emergency evaluation.
  4. Confirm Daraxonrasib Metabolism And Interaction List
    Fill in whether daraxonrasib is a CYP3A4 substrate/inhibitor/inducer, P-gp/BCRP substrate, and any acid-reducing agent restrictions. Then list specific contraindicated/avoid medications per protocol/label (e.g., strong CYP inhibitors/inducers, QT-prolongers).
  5. Patient Handout Rash Prevention And Escalation
    Provide a standardized rash kit and instructions: fragrance-free emollient twice daily, gentle cleanser, avoid hot showers, SPF 30+ broad-spectrum daily, sun-avoidance, when to start topical steroid and antihistamine, and when to call clinic (new blistering, mucosal sores, fever).
tosprivacy